Cannasouth Addresses Shareholder Queries
Cannasouth Limited (subject to deed of company arrangement) (NZX:CBD) (“CBD”) has received queries from shareholders during the course of the voluntary administration process and Deed of Company Arrangement to date 
© 2024 sharechat.co.nz Tue, 5 Nov 1:05pm Cannasouth reports full-year loss but revenue growth
The medicinal cannabis company reported a full-year net loss of $8.8 million in the year ended December, while revenue was up 11 percent.
© 2024 RadioNZ Mon, 4 Mar 12:05am CBD - Cannasouth Investor Call
Cannasouth Limited (NZX:CBD) will host an online investor call on Wednesday, 29 November 2023, to discuss the Company’s strategy to drive sales of its recently verified products and meet its revenue and operating cashflow targets
© 2024 sharechat.co.nz Mon, 27 Nov 4:45pm  CBD - Cannasouth Announces Integration Restructure
Cannasouth Ltd (NZX: CBD) announced today that following the merger with Eqalis, effective 1 June 2023, opportunities for cost rationalisation through operational efficiencies and greater focus were identified
© 2024 sharechat.co.nz Tue, 3 Oct 11:45am CBD - Regulatory Changes to Bolster NZ Medicinal Cannabis Sector
Cannasouth Limited (NZX:CBD) is pleased to share forthcoming regulatory changes that are poised to have a significant impact on Cannasouth's growth trajectory and our industry competitiveness
© 2024 sharechat.co.nz Tue, 1 Aug 2:10pm CBD - Eqalis Cannabis-Based Ingredient Successfully Verified
Cannasouth Limited, (NZX:CBD), is pleased to announce that Eqalis Pharmaceuticals Ltd’s’ first cannabis-based ingredient has been successfully verified by the Medicinal Cannabis Agency (Agency) as meeting the New Zealand minimum quality standa
© 2024 sharechat.co.nz Thu, 22 Jun 11:00am CBD - Cannasouth Receives GMP Licence to Manufacture Medicines
Cannasouth Limited (NZX:CBD) is pleased to announce it has received its Licence to Manufacture Medicines to produce dried cannabis flower (to the globally recognised GMP standard) at its cultivation facility
© 2024 sharechat.co.nz Thu, 18 May 4:00pm  |
|
 |
 
CBD - Subsidiaries parties to Deed of Company Arrangement
Cannasouth Limited (NZX:CBD) announces that, following the Watershed Meeting on 7 June 2024, its subsidiaries, Cannasouth Cultivation Limited, Eqalis Pharmaceuticals Limited, Eqalis Innovations Limited
© 2024 sharechat.co.nz Mon, 1 Jul 2:25pm CBD - Recording and Presentation of Investor Call
Cannasouth Limited (NZX:CBD) hosted an online investor call on Wednesday, 29 November 2023, to discuss the Company’s strategy to drive sales of its recently verified products and meet its revenue and operating cashflow targets
© 2024 sharechat.co.nz Thu, 30 Nov 11:52am CBD - Cannasouth Announces Opening of Rights Offer
As announced to the market on 13 November, Cannasouth Limited (NZX:CBD) announced the launch of a 1 for 8 pro-rata renounceable rights issue to raise up to circa $5.6 million ("Rights Offer”)
© 2024 sharechat.co.nz Wed, 22 Nov 11:45am CBD - Successful Verification for Oral Solution Products
Cannasouth Limited (NZX:CBD) is pleased to announce the successful assessment of its first two CBD Oral Solutions products by the Medicinal Cannabis Agency (Agency)
© 2024 sharechat.co.nz Fri, 27 Oct 4:23pm Cannasouth exports first Cannabis-based API
Cannasouth Limited (NZX:CBD) has exported to Australia its first commercial shipment of its high-purity cannabidiol (CBD) isolate, a cannabis-based, active pharmaceutical ingredient (API). This is a first for Aotearoa New Zealand’s medicinal cannabi
© 2024 sharechat.co.nz Thu, 14 Sep 12:05am  Capital Raise Complete, Merger with Eqalis Unconditional
Cannasouth advises that it has closed its offer to Cannasouth shareholders and to shareholders of Eqalis Group New Zealand Limited (“The Offers”)
© 2024 sharechat.co.nz Tue, 30 May 11:46am
|
|
